Topic

Toggle navigation

FDA

This content is from: Premium

These Biopharma Funds Made a Comeback Last Year

While some funds posted huge losses in 2022, several others managed to turn sharp losses into profitability.
By Stephen Taub
January 19, 2023
This content is from: Portfolio

How to Profit from Faster FDA and Better Science

Buoyed by advances in genomics and a speedier FDA, health care investors are seeking moneymaking opportunities among pharmaceuticals companies developing expensive, new drugs.
By Fran Hawthorne
August 01, 2012
This content is from: Portfolio

FDA Inaction Could Be Preventing Investment in Cheaper Drugs

Companies that make biosimilars — off-patent versions of biological drugs that are significantly cheaper than the originals — have a problem: They need investment, but they can’t get that investment without FDA approval. And the FDA is dragging its heels.
By Udayan Gupta
August 24, 2011
This content is from: Portfolio

The FDA’s Pulse Quickens

After years of complaints that it was too protectionist, the Food and Drug Administration seems to have entered an era of faster approvals.
By Fran Hawthorne
August 01, 2012
This content is from: Portfolio

This Hedge Fund Is ‘Reasonably Confident’ a Covid-19 Vaccine Will Be Approved This Year

MKP Capital has also calculated the odds of the FDA approving a vaccine before the U.S. presidential election.
By Christine Idzelis
September 10, 2020
This content is from: Portfolio

Miles White of Abbott Laboratories: On the mend

Long before Merck and Pfizer ran into trouble with painkillers, Abbott Labs had to swallow a bitter pill from the FDA. But CEO Miles White made sure it had a therapeutic effect.

March 14, 2005
See More Articles